Vascularized Lymph Vessel Transfer for Extremity Lymphedema - Is Transfer of Lymph Node Still Necessary?

Wei F. Chen, MD, FACS; Maria McNurlen, MD; Johnson Ding, MD; Mindy Bowen, RN

Center for Lymphedema Research and Reconstruction, Division of Plastic and Reconstructive Surgery, Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

ABSTRACT

Introduction: Lymphaticovenular anastomosis (LVA) and vascularized lymph node transfer (VLNT) are established lymphedema treatments. However, LVA is only effective for early disease and VLNT can cause donor-site lymphedema and contour deformity. Vascularized lymph vessel transfer (VLVT) is free of these limitations. We described our experience of a new VLVT technique.

Patients and Methods: Patients with fluid-predominant lymphedema who failed lymphedema therapy were offered surgical intervention. Those with early injury seen on indocyanine green (ICG) lymphography were treated with LVA. Superficial iliac artery perforator (SCIP)-based lymph vessel transfer was offered to those with advanced injury. After lymphographic mapping of the lymph vessels and doppler perforator mapping, thin SCIP flap was harvested. Only the superficial fat layer was included to recruit the lymph vessels while preserving the lymph nodes. The flaps were vascularized with end-to-side or perforator-to-perforator anastomosis.

Results: The SCIP-based lymph vessel flap was performed in 6 patients with extremity lymphedema. Four had upper and 2 had lower extremity disease. One had partial (< 5%) flap loss which was managed with local wound care. All others had uneventful postoperative course. Follow-up was 13-27 months. All experienced prompt relief of symptoms and circumference reduction. At 1 year out, all demonstrated durable symptomatic improvement with correlating improvement on ICG lymphography. Three of 6 patients achieved minimal compression garment use. None developed donor site lymphedema.

Conclusions: Our early experience of the SCIP-based VLVT showed promising result in treating extremity lymphedema and suggested it as a viable alternative treatment to LVA and VLNT.

INTRODUCTION

Vascularized lymph node transfer (VLNT) and lymphaticovenular anastomosis (LVA) are established microsurgical and supermicrosurgical treatments of extremity lymphedema and are increasingly performed worldwide [1,2]. By harvesting healthy lymph nodes from another part of the body and re-vascularizing them at the affected limb, VLNT is thought to directly drain the edematous limb via “pump” mechanism [3-5] and lymphangiogenesis [3,6,7]. Since its inception in the 80s, groin VLNT based on superficial circumflex iliac vessels had been performed around the world with consistent success [3,8-11]. No serious donor site complications were reported until 2013, when donor leg lymphedema following groin lymph node harvest was initially reported [12,13]. No serious donor site complications were reported until 2013, when donor leg lymphedema following groin lymph node harvest was initially reported [12,13]. The concern of donor site lymphedema prompted the subsequent developments of submental [14-16], supraclavicular [2,17,18], lateral thoracic [7,19-22], and most recently, omental [23-25] and jejunal mesenteric [26] lymph node transfers. LVA is free of the risk of donor site lymphedema, but it is only effective in patients with early disease.

Vascularized lymph vessel transfer (VLVT) represented a conceptual departure from the accepted belief that transfer of nodal tissue is required for lymphedema restoration [27]. Based on the first dorsal metatarsal vessels, Koshima et al. proposed the original VLVT for patients with advanced lymphedema and reported favorable outcomes [27]. Similar to VLNT, VLVT is thought to mediate its therapeutic efficacy through the peristaltic, pumping actions of healthy lymphatic vessels [4]. We propose a new VLVT technique based on a different donor site and describe our early experience.

PATIENTS AND METHODS

Surgical interventions were offered to patients who failed complex decongestive therapy (CDT) as determined by our certified lymphedema therapists. Physiologic procedures including LVA and VLVT were offered to patients with fluid-predominant disease. Fluid-predominant state was determined by the presence of prominent pitting on physical examination, quantitative bioimpedance spectroscopy showing significant limb fluid excess, and magnetic resonance imaging showing minimal lipodystrophy and subcutaneous fibrosis. The selection between LVA and VLVT was based on the severity of lymphatic injury seen on indocyanine green (ICG) lymphographic findings. Patients with preserved, functioning lymph vessels characterized by “linear” lymphographic pattern were offered LVA. Conversely, complete absence of “linear” pattern and/or the presence of “diffuse” pattern suggestive of severe lymphatic injury indicated VLVT. Therefore, the inclusion criteria are fluid-predominant disease and advanced lymphatic injury. The exclusion criteria are solid-predominant disease and early lymphatic injury treatable with LVA.

Surgical Technique

Groin superficial lymph vessels were delineated with ICG lymphography by placing four 0.05 ml intradermal injections of 0.25% ICG solution lateral to the anterior superior iliac spine. After identifying the locations of perforators with Doppler ultrasound, a 10 x 6 cm superficial circumflex iliac artery perforator (SCIP) flap was designed over the perforators to recruit the mapped lymph vessels (Figure 1). The inferior skin incision was made and deepened to include 3-5 mm subcutaneous fat. Cephalad-directed, lateral-to-medial dissection was performed to identify the superficial and deep branch perforators of the superficial circumflex iliac artery (SCIA). The dissection plane was maintained immediately superficial to Scarpa’s fascia to exclude lymph nodes from the flap (Figure 2). In obese patients, the dissection proceeded along a...
non-anatomic plane superficial to the superficial fascia to keep the flap thin (Figure 2, 3). Upon confirming perforator entry into the flap, the superior skin incision was committed. Retrograde pedicle dissection was performed until adequate pedicle length was achieved. The presence of lymph vessels in the flap was confirmed by scanning the adiposal surface of the flap with Spy ELITE (Kalamazoo, Michigan) (Figure 4). The VLVT flap was transferred to the wrist using radial artery as the recipient vessel for arm lymphedema and to the ankle using posterior tibial artery as the recipient vessel for leg disease. Perforator-to-perforator anastomosis was preferentially performed when feasible. For vessels 0.5 to 0.8 mm, 11-0 nylon was used for anastomosis. For those smaller than 0.5 mm, 12-0 nylon was used. In the absence of recipient perforator, end-to-side anastomosis was required due to size mismatch between the flap arterial pedicle and the recipient artery. Only vascular anastomoses and no lymphatico-venular or lymphatico-lymphatical anastomosis were performed. Full-thickness skin excision with dimension identical to the VLVT flap was performed at the recipient site to facilitate flap inset (Figure 5). The groin donor wound was closed primarily.

Postoperative Care
The recipient limb was elevated for a week. Bandage compression of the recipient limb and ambulation for patients with lower extremity disease began on the second postoperative week. On the fourth week, all patients resumed CDT and began wearing newly fitted 30-40 mmHg compression garments for sixteen hours a day. Weaning of compression garment began after six months under the supervision of the patients' therapists.

Figure 1. Groin lymph vessels were mapped with ICG lymphography with intradermal injection of 0.25% ICG lateral to ASIS. A thin SCIP-based VLVT flap was designed by identifying SCIA perforators along a line extending from groin crease to ASIS. The width was designed with pinch test to ensure subsequent primary closure of the donor wound. ASIS, anterior superior iliac spine; ICG, indocyanine green; SCIA, superficial circumflex iliac artery; SCIP, superficial iliac artery perforator; VLVT, vascularized lymph vessel transfer.

Figure 2. The SCIP-based VLVT flap was typically harvested immediately superficial to the Scarpa's fascia to preserve the lymph nodes that are anatomically situated deep to the Scarpa's fascia. This creates a thin flap that facilitates flap inset. In obese patients, the above technique would produce a thick flap. In these patients, we harvested the flap along a non-anatomic, artificially created plane created at 3-5 mm under the dermis. SCIP, superficial iliac artery perforator; VLVT, vascularized lymph vessel transfer.

Figure 3. Profile view of a thin SCIP-based VLVT flap. By maintaining a 3-5 mm thickness during flap elevation, the resulting flap would include subdermal lymphatic vessels while minimizing flap bulk. This facilitated flap inset and prevented contour deformity frequently seen in lymph node transfer. Superficial circumflex iliac artery superficial branch perforator (right) and superficial circumflex iliac vein (left) could be seen. SCIP, superficial iliac artery perforator; VLVT, vascularized lymph vessel transfer.

Figure 4. Dense lymphatic network seen in the VLVT flap (red arrows). The image was taken from the adiposal side of the flap. The bright areas on the left side represented the ICG injection site. No lymph nodes were seen in the flap. ICG, indocyanine green; VLVT, vascularized lymph vessel transfer.

Figure 5. Comparison of lymph node flap inset and lymph vessel flap inset. Contour deformity was not avoidable due to the associated tissue bulk in a lymph node flap. In this case, we could not complete the flap inset due to venous congestion from pedicle compression with complete flap inset (panel A). The thin lymph vessel flap in combination with recipient site skin excision facilitated inset that did not disrupt anatomic contour (panel B).
Outcome Evaluation

All patients were evaluated at preoperatively, and at 3-, 6-, and 12-month postoperatively with patient report, examination by the surgeon, circumference measurements, and indocyanine green lymphography. Circumference measurements were performed at elbow crease, and two levels above and below at 5 cm interval for arms, and at popliteal crease and two levels above and below at 10 cm interval for legs. Indocyanine green lymphography was performed with 0.25% indocyanine green with our standardized technique previously described [28]. Data were analyzed using Students T tests. Statistical analysis was performed with Stata 15.1 (StataCorp, College Station, Texas, USA). Unless specified, all statistical testing assumes paired two tail t-test with P < 0.05 considered as statistically significant.

RESULTS

Six patients with fluid-predominant limb lymphedema underwent SCIP-based VLVT (Table 1). Five had Campisi stage III and 1 had Campisi stage II disease. All were deemed inappropriate candidates for LVA due to absence of “linear” or presence of “diffuse” pattern on ICG lymphography. All were female aged 41-69, all failed CDT, and all refused vascularized lymph node transfer due to risk of donor site lymphedema. Four had upper and 2 had lower extremity disease. Duration of disease at the time of surgery ranged 2-27 years. For upper extremity disease, the side with more robust SCIA vascular anatomy seen on computed tomography angiography was selected as donor site. For lower extremity disease, the contralateral groin was used.

Table 1. Patients and Data

<table>
<thead>
<tr>
<th>Patient</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>F</td>
<td>F</td>
<td>F</td>
<td>F</td>
<td>F</td>
<td>F</td>
</tr>
<tr>
<td>Age</td>
<td>62</td>
<td>41</td>
<td>65</td>
<td>68</td>
<td>69</td>
<td>54</td>
</tr>
<tr>
<td>Campisi</td>
<td>III</td>
<td>III</td>
<td>III</td>
<td>III</td>
<td>III</td>
<td>II</td>
</tr>
<tr>
<td>Extremity</td>
<td>Right leg</td>
<td>Left arm</td>
<td>Right arm</td>
<td>Right arm</td>
<td>Left arm</td>
<td>Left leg</td>
</tr>
<tr>
<td>Disease Duration (years)</td>
<td>10</td>
<td>7</td>
<td>27</td>
<td>9</td>
<td>16</td>
<td>2</td>
</tr>
<tr>
<td>Postoperative Relief of Symptoms</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Circumferences Before (cm)</td>
<td>54.4/42.1/41.5/39/34</td>
<td>28.3/27.2/24/26.6/25.2</td>
<td>26.5/28/27.5/27/24.5</td>
<td>26.6/32/27/33/8/28</td>
<td>34.4/32.1/32.7/33.9/31</td>
<td>46.5/38.5/34.2/36.1/28.4</td>
</tr>
<tr>
<td>Circumferences After (cm)</td>
<td>54/24/36/38.4/32.1</td>
<td>27.2/26.3/25.2/25/22.8</td>
<td>26/26.1/25.5/26.2/23.8</td>
<td>27.7/28/38.2/30/26.3</td>
<td>26.4/27/26.6/28.2/27.8</td>
<td>43.3/37/32.5/35.8/27.5</td>
</tr>
<tr>
<td>P-Value (Circumference)</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Circumference measurements for arms were performed at elbow crease, and two levels above and below at 5 cm interval. For legs, they were performed at popliteal crease, and two levels above and below at 10 cm interval. The postoperative circumferences at 1 year were shown. The postoperative circumference reduction at 1 year was statistically significant.
All flap survived, and 1 patient had (< 5%) partial flap loss which was successfully managed with local wound care. Postoperative follow-up ranged 13-27 months. All began to experience notable edema reduction and relief of symptoms (including pain, paresthesia, rigidity, and decrease range of motion) early in the postoperative course at 1-3 weeks postoperatively. Additional, progressive improvements were seen in all patients over time. At 6 months following surgery, two patients were able to greatly reduce compression garment use to only wearing the garment when heavy exertion was expected. At 1 year out, another patient (total of 3 of 6 patients) achieved the state of minimal use of compression garment of 1-2 days per week. None was able to completely stop using compression. All demonstrated stable improvements at 1 year out based on ICG lymphography and statistically significant reduction in circumference measurements (Table 1). None developed donor site lymphedema, both clinically and when screened with ICG lymphography postoperatively (Figure 6). All patients were satisfied with the surgical outcomes.

CASE REPORTS

Case 1

A 41-year-old female presented with post-mastectomy left arm lymphedema which started immediately following bilateral mastectomies for left breast carcinoma, left axillary lymph node dissection, chemotherapy, and radiation therapy. Her symptoms included diffuse hand/arm edema, pain, and paresthesia. She underwent delayed bilateral breast reconstruction with implant for her right breast and implant/latissimus dorsi flap for her left breast. This patient was a therapist and had been performing CDT herself. Upon presentation to our center, she reported a 5-year history of progressive worsening of her arm edema and wrist/forearm pain, despite rigorous CDT. Her diagnostic workup confirmed Campisi stage II, fluid-predominant disease with ICG lymphography showing “stardust” and “diffuse” pathologic patterns extending from her...
A 54-year-old female presented with acquired left leg lymphedema following hysterectomy, pelvic lymph node dissection, and chemotherapy for uterine carcinoma. Her symptoms included lower abdominal, left hip, and leg edema. The patient experienced prompt relief of her lymphedema symptoms immediately following the surgery. During the 6 months following the surgery, she noted progressive improvement in arm edema, pain, and paraesthesia. She also experienced increased exercise tolerance of her left arm. She began to swim regularly, which she was unable to do before surgery. At her one-year follow-up, the patient reported no abdominal/hip/limb edema or discomfort and no cellulitis. She also demonstrated favorable limb circumference reduction (Figure 11) and ICG lymphographic changes (Figure 10B). She was only wearing her compression garment selectively.

Figure 11. Postoperative reduction in leg/thigh circumferences at one year from surgery. Shown are preoperative (A) and postoperative (B) measurements. Again, the reduction rates varied depending on the levels, and the highest reduction rate was seen at the most proximal level. Circumference reduction rate= [(a-b)-(c-d)] / (a-b) where a= preoperative lesion leg, b=preoperative healthy leg, c= postoperative healthy leg.

Vascularized lymph node transfer is considered by most to be the procedure of choice for patients with advanced, fluid predominant extremity lymphedema [29-34]. While technical refinements over the years have made VLNT a safer procedure, the risk of donor site lymphedema is only lowered and not eliminated [12,13,35-38]. Recent developments of intra-abdominal lymph node transfers promised to resolve the risk of donor site lymphedema but exposed the patients to complications associated with intraperitoneal surgery [26,38].

Previously, we offered VLNT for patients with late fluid predominant disease who were not candidates for LVA. While we did not observe donor-site lymphedema, it remained a dreaded potential complication that caused significant anxiety in both the patients and the surgeons. Furthermore, once the excitement of initial improvement waned, many patients complained about contour deformity created by the bulky lymph node flap. Combining the above with the predilection of patients refusing VLNT after learning about the risk of donor site lymphedema, we began to seek alternative treatment.

Koshima et al. proposed the concept of lymph vessel-only vascularized transfer based on first dorsal metatarsal artery (FDMA) to treat extremity lymphedema and reported favorable outcomes [27]. The study went on to hypothesize the functioning smooth muscles lining the healthy lymphatic vessels contracting and helping to transport accumulated lymph fluid into the venous system. We had favorable experience with the FDMA-based VLNT and observed results consistent with what Koshima et al reported. However, our patients also frequently had donor wound breakdown (Figure 12). Thin SCIP-based VLVT is theoretically a superior source of vascularized lymph vessels and donor site because 1) its anatomy is familiar to plastic surgeons, 2) it contains higher lymph vessel density than the FDMA donor site, and 3) it has a track record of safety as demonstrated by Hong et al and others [37,39-44]. Since groin lymph nodes are anatomically situated deep to the superficial fascia, flap harvest superficial to the superficial fascia ensures preservation of the lymph nodes. Another advantage of the SCIP-based VLVT is superior cosmesis. By excising a size-matched area of recipient site skin prior to insetting the thin VLVT flap, the contour deformity classically associated with VLNT and the need for secondary debulking [45] are prevented. For the above-mentioned reasons, we preferred the SCIP-based VLVT over the FDMA-based VLNT.

During dissection of the SCIP-based VLVT, groin superficial fascia can be identified as a thin, fibrous plane between the superficial and deep fat layers. The plane is particularly distinct in the lateral aspect adjacent to the anterior superior iliac spine. The two fat layers can be distinguished by observing the relative fat lobule sizes with the superficial fat lobules being smaller and more densely packed. The dissection can be performed under ICG lymphographic guidance to ensure nodal preservation and recruitment of only lymph vessels.
Vascularized lymph vessel transfer demonstrated promising results in treating extremity lymphedema without the inclusion of nodal tissue. SCIP-based VLVT using the thin SCIP flap harvest technique may potentially offer higher therapeutic efficacy than the FDMA-based VLVT. Our experience suggested the feasibility of the inclusion of SCIP-based VLVT in the reconstructive microsurgeon’s armamentarium for treating extremity lymphedema.

CONCLUSIONS

Vascularized lymph vessel transfer demonstrated promising results in treating extremity lymphedema without the inclusion of nodal tissue. SCIP-based VLVT using the thin SCIP flap harvest technique may potentially offer higher therapeutic efficacy than the FDMA-based VLVT. Our experience suggested the feasibility of the inclusion of SCIP-based VLVT in the reconstructive microsurgeon’s armamentarium for treating extremity lymphedema.
28. Chen WF, Zhao H, Yamamoto T, Hara H, Ding J. Indocyanine green lymphograph-
29. Raju A, Chang DW. Vascularized lymph node transfer for treatment of lymphede-
38. Coriddi M, Wee C, Meyerson J, Eiferman D, Skoracki R. Vascularized jejunal mesen-
44. Myung Y, Yim S, Kim BK, surgery h. A comparison of axial circumference between superficial circumflex iliac artery perforator flap and other workhorse flaps in dor-
cussion 742-733.